Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Apr 16

PMID 32290213

Citations 62

Authors

Vilashini Rajaratnam

Mohammad Mohiminul Islam

Maixee Yang

Rachel Slaby

Hilda Martinez Ramirez

Shama Parveen Mirza

Affiliations

Soon will be listed here.

Abstract

Glioblastoma is one of the most common and detrimental forms of solid brain tumor, with over 10,000 new cases reported every year in the United States. Despite aggressive multimodal treatment approaches, the overall survival period is reported to be less than 15 months after diagnosis. A widely used approach for the treatment of glioblastoma is surgical removal of the tumor, followed by radiotherapy and chemotherapy. While there are several drugs available that are approved by the Food and Drug Administration (FDA), significant efforts have been made in recent years to develop new chemotherapeutic agents for the treatment of glioblastoma. This review describes the molecular targets and pathogenesis as well as the current progress in chemotherapeutic development and other novel therapies in the clinical setting for the treatment of glioblastoma.

Citing Articles

Innovative perspectives on glioblastoma: the emerging role of long non-coding RNAs.

Doghish A, Mahmoud A, Abd-Elmawla M, Zaki M, Aborehab N, Hatawsh A Funct Integr Genomics. 2025; 25(1):43.

PMID: 39992471 DOI: 10.1007/s10142-025-01557-6.

Citronellol Induces Apoptosis via Differential Regulation of Caspase-3, NF-κB, and JAK2 Signaling Pathways in Glioblastoma Cell Line.

Malik M, Ali S, Ali A, Alanzi A, Atif M, Alharbi H Food Sci Nutr. 2025; 13(1):e4678.

PMID: 39803280 PMC: 11717069. DOI: 10.1002/fsn3.4678.

Nanostructured lipid carriers for enhanced batimastat delivery across the blood-brain barrier: an in vitro study for glioblastoma treatment.

Horta M, Soares P, Sarmento B, Leite Pereira C, Lima R Drug Deliv Transl Res. 2025; .

PMID: 39760929 DOI: 10.1007/s13346-024-01775-8.

The role of sphingolipid rheostat in the adult-type diffuse glioma pathogenesis.

Karmelic I, Jurilj Sajko M, Sajko T, Rotim K, Fabris D Front Cell Dev Biol. 2024; 12:1466141.

PMID: 39723240 PMC: 11668798. DOI: 10.3389/fcell.2024.1466141.

Regulation of autophagy by non-coding RNAs in human glioblastoma.

Molavand M, Ebrahimnezhade N, Kiani A, Yousefi B, Nazari A, Majidinia M Med Oncol. 2024; 41(11):260.

PMID: 39375229 DOI: 10.1007/s12032-024-02513-3.

References

Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B . Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017; 318(23):2306-2316. PMC: 5820703. DOI: 10.1001/jama.2017.18718. View

Weller M, Butowski N, Tran D, Recht L, Lim M, Hirte H . Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017; 18(10):1373-1385. DOI: 10.1016/S1470-2045(17)30517-X. View

Krauze A, Mackey M, Rowe L, Chang M, Holdford D, Cooley T . Late toxicity in long-term survivors from a phase 2 study of concurrent radiation therapy, temozolomide and valproic acid for newly diagnosed glioblastoma. Neurooncol Pract. 2018; 5(4):246-250. PMC: 6213944. DOI: 10.1093/nop/npy009. View

Sepulveda-Sanchez J, Vaz M, Balana C, Gil-Gil M, Reynes G, Gallego O . Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. Neuro Oncol. 2017; 19(11):1522-1531. PMC: 5737732. DOI: 10.1093/neuonc/nox105. View

Kaley T, Panageas K, Mellinghoff I, Nolan C, Gavrilovic I, DeAngelis L . Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. J Neurooncol. 2019; 144(2):403-407. PMC: 7493746. DOI: 10.1007/s11060-019-03243-7. View

Nayak L, de Groot J, Wefel J, Cloughesy T, Lieberman F, Chang S . Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol. 2017; 132(1):181-188. PMC: 5588922. DOI: 10.1007/s11060-016-2357-9. View

Huang J, Chaudhary R, Cohen A, Fink K, Goldlust S, Boockvar J . A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. J Neurooncol. 2019; 142(3):537-544. DOI: 10.1007/s11060-019-03125-y. View

Yu A, Faiq N, Green S, Lai A, Green R, Hu J . Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. J Neurooncol. 2017; 134(2):357-362. PMC: 6135089. DOI: 10.1007/s11060-017-2533-6. View

Doan N, Alhajala H, Al-Gizawiy M, Mueller W, Rand S, Connelly J . Acid ceramidase and its inhibitors: a drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency. Oncotarget. 2018; 8(68):112662-112674. PMC: 5762539. DOI: 10.18632/oncotarget.22637. View

10.

Doan N, Nguyen H, Montoure A, Al-Gizawiy M, Mueller W, Kurpad S . Acid ceramidase is a novel drug target for pediatric brain tumors. Oncotarget. 2017; 8(15):24753-24761. PMC: 5421885. DOI: 10.18632/oncotarget.15800. View

11.

Corso C, Bindra R, Mehta M . The role of radiation in treating glioblastoma: here to stay. J Neurooncol. 2017; 134(3):479-485. DOI: 10.1007/s11060-016-2348-x. View

12.

Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D . HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017; 3(8):1094-1101. PMC: 5747970. DOI: 10.1001/jamaoncol.2017.0184. View

13.

van den Bent M, Eoli M, Sepulveda J, Smits M, Walenkamp A, Frenel J . INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol. 2019; 22(5):684-693. PMC: 7229258. DOI: 10.1093/neuonc/noz222. View

14.

Taphoorn M, Dirven L, Kanner A, Lavy-Shahaf G, Weinberg U, Taillibert S . Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018; 4(4):495-504. PMC: 5885193. DOI: 10.1001/jamaoncol.2017.5082. View

15.

McCracken D, Celano E, Voloschin A, Read W, Olson J . Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma. J Neurooncol. 2016; 130(1):193-201. DOI: 10.1007/s11060-016-2234-6. View

16.

Mann J, Ramakrishna R, Magge R, Wernicke A . Advances in Radiotherapy for Glioblastoma. Front Neurol. 2018; 8:748. PMC: 5775505. DOI: 10.3389/fneur.2017.00748. View

17.

Brandes A, Gil-Gil M, Saran F, Carpentier A, Nowak A, Mason W . A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. Oncologist. 2018; 24(4):521-528. PMC: 6459244. DOI: 10.1634/theoncologist.2018-0290. View

18.

Mecca C, Giambanco I, Donato R, Arcuri C . Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence. Dis Markers. 2019; 2018:9230479. PMC: 6312595. DOI: 10.1155/2018/9230479. View

19.

Chinnaiyan P, Won M, Wen P, Rojiani A, Werner-Wasik M, Shih H . A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. Neuro Oncol. 2017; 20(5):666-673. PMC: 5892159. DOI: 10.1093/neuonc/nox209. View

20.

Cohen M, Shen Y, Keegan P, Pazdur R . FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009; 14(11):1131-8. DOI: 10.1634/theoncologist.2009-0121. View